Articles tagged "Multicenter studies"

2020 American Transplant Congress
Atrial Fibrillation Predicts Inferior Survival in Liver Transplant Recipients of Advanced Age in a Large Multicenter U.S. Cohort
M. German¹, A. Hristov¹, A. Lee¹, F. Osman¹, A. Kwong², D. Devuni³, C. Wang⁴, J. Boike⁵, J. Jo⁵, L. VanWagner⁵, M. Serper⁶, R. Sharma⁷, E. Verna⁷, J. Shor³, A. Koteish⁸, G. Sehmbey⁹, A. Seetharam⁹, N. John², Y. Patel¹⁰, M. Kappus¹⁰, T. Couri¹¹, S. Paul¹¹, R. Salgia¹², Q. Nhu¹³, C. Frenette¹³, J. Lai⁴, A. Goel², E. Spengler¹
¹U of Wisconsin, Madison, WI, ²Stanford, Palo Alto, CA, ³U of Massachusetts, Worcester, MA, ⁴U of California, San Francisco, CA, ⁵Northwestern, Chicago, IL, ⁶U of Pennsylvania, Philadelphia, PA, ⁷Columbia, New York, NY, ⁸Florida Hospital, Orlando, FL, ⁹U of Arizona, Phoenix, AZ, ¹⁰Duke, Durham, NC, ¹¹U of Chicago, Chicago, IL, ¹²Henry Ford Hospital, Detroit, MI, ¹³Scripps, San Diego, CA
*Purpose: More liver transplants (LT) are being performed in patients >65 years (y) - a population with higher rates of cardiovascular (CV) disease. It is…
2020 American Transplant Congress
Transarterial Chemoembolization and Radio-Embolization are Similarly Efficacious in Achieving Successful Hepatocellular Carcinoma (HCC) Down-Staging: Results from the Multicenter Evaluation of Reduction in Tumor Size Before Liver Transplantation (MERITS-LT) Consortium
N. Mehta¹, J. Guy², C. Frenette³, P. Tabrizian⁴, M. Hoteit⁵, N. Parikh⁶, T. Ghaziani⁷, R. Dhanasekaran⁷, J. L. Dodge¹, M. L. Holzner⁴, S. Florman⁴, F. Yao¹
¹UCSF, SF, CA, ²CPMC, SF, CA, ³Scripps Hospital, La Jolla, CA, ⁴Mt Sinai, NY, NY, ⁵U. Pennsylvania, Philadelphia, PA, ⁶U. Michigan, Ann Arbor, MI, ⁷Stanford, Palo Alto, CA
*Purpose: United Network of Organ Sharing (UNOS) Region 5 has reported excellent liver transplantation (LT) outcomes after successful down-staging (DS) in HCC patients exceeding Milan…
2020 American Transplant Congress
Reactivation of BK Polyomavirus after Kidney Transplantation: A Multi-Center Collaboration Examining the Impact of Adherence to a Screening Protocol on Clinical Outcomes
R. Rogers¹, F. Cheema², M. Chobanian³, Z. Ebcioglu², H. Gilligan⁴, R. Gohh¹, N. Goyal⁵, M. Pavlakis⁶, N. Rodig⁷, A. Rossi⁸, J. Singh², C. S. Tan⁶
¹Warren Alpert Medical School of Brown University, Providence, RI, ²Hartford Hospital, Hartford, CT, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Massachusetts General Hospital, Boston, MA, ⁵Tufts University School of Medicine, Boston, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Boston Children's Hospital, Boston, MA, ⁸Maine Medical Center, Portland, ME
*Purpose: Reactivation of BK polyomavirus (BK) after kidney transplantation (KT) is common and can lead to adverse clinical outcomes such as allograft nephropathy (BKAN). In…
2020 American Transplant Congress
TRANSBIO Study: Clinical Evaluation of Immunobiogram, a Novel In Vitro Diagnostic Immunoassay to Guide Adjustment of Immunosuppressive Therapy in Kidney Transplantation
J. Pascual¹, C. Jiménez², M. Krajewska³, C. Kotton⁴, D. Seron⁵, J. Portolés⁶, O. Witzke⁷, S. S. Sorensen⁸, A. Andrés⁹, T. Díez¹⁰, A. Ortega¹⁰, I. Portero¹⁰
¹Consorci Mar Parc de Salut, Barcelona, Spain, ²La Paz Hospital, Madrid, Spain, ³Wroclaw Medical University, Wroclaw, Poland, ⁴Massachusetts General Hospital, Boston, MA, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, ⁷University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁸Rigshospitalet, Copenhagen, Denmark, ⁹12 de Octubre Hospital, Madrid, Spain, ¹⁰Biohope Scientific Solutions for Human Health SL, Madrid, Spain
*Purpose: Immunobiogram (IMBG) is a first-in-class blood-based pharmacodynamic immunoassay that provides the sensitivity/resistance profile of each patient’s lymphocytes to a panel of immunosuppressive drugs (IS).…
2020 American Transplant Congress
The State of Interventional Clinical Trials in Solid Organ Transplant: Insights from a Systematic Analysis of Clinicaltrials.gov
A. C. Swaminathan¹, J. Li¹, K. Chiswell¹, W. McManigle¹, I. O’Doherty², W. Fitzsimmons³, J. L. Todd¹, S. Tibbs⁴, S. M. Palmer¹
¹Duke Clinical Research Institute, Durham, NC, ²Critical Path Institute, Tuscan, AZ, ³Fitzsimmons LLC, Chicago, IL, ⁴Duke University, Durham, NC
*Purpose: The approach to immunosuppression after solid organ transplant has remained relatively unchanged for almost 20 years, despite the high prevalence of immunosuppression-related complications and…
2020 American Transplant Congress
A Monocyte-Derived MicroRNA Signature for Antibody-Mediated Rejection in Kidney Transplantation
C. Tinel¹, B. Lamarthée¹, F. Von Tokarski¹, M. Rabant², C. Legendre¹, W. Gwinner³, M. Naesens⁴, P. Marquet⁵, D. Anglicheau¹
¹Kidney Transplantation, Inserm U1151, Necker Hospital, Paris, France, ²Pathology, Necker Hospital, Paris, France, ³Nephrology, Hannover Medical School, Hannover, Germany, ⁴Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium, ⁵Nephrology, Dialysis and Transplantation, Inserm U850, Limoges University Hospital, Limoges, France
*Purpose: MicroRNAs (miRNAs) are small noncoding RNAs which regulate mRNA expression at the posttranscriptional level. We investigated blood miRNAs as non-invasive biomarkers in kidney transplantation…
2020 American Transplant Congress
RNA Sequencing of Urine RNA Samples for Biomarker Discovery
K. S. Keslar¹, D. Margeta¹, M. Abecassis², J. J. Friedewald², P. S. Heeger³, R. L. Fairchild¹
¹Cleveland Clinic, Cleveland, OH, ²Northwestern University, Chicago, IL, ³Icahn School of Medicine, New York, NY
*Purpose: An accurate, noninvasive assay based on urinary gene expression profiles would be a powerful tool for clinical management of kidney transplant patients. We have…
2020 American Transplant Congress
TRANSFORM Study (NCT01950819): Application of the Ibox Clinical Trial Simulation Tool to Project Long-Term Kidney Allograft Outcome
G. Divard¹, O. Aubert¹, M. Raynaud¹, J. Pascual², F. Vincenti³, P. Bernhardt⁴, C. Legendre¹, A. Loupy¹, .. on behalf of TRANSFORM Investigators⁵
¹INSERM U970, Paris Transplant Group, Paris, France, ²Department of Nephrology, Hospital del Mar/Universitat Autònoma de Barcelona, Barcelona, Spain, ³Department of Surgery/Kidney Transplant Service, University of California, San Francisco, CA, ⁴Research and Development, Novartis Pharma AG, Basel, Switzerland, ⁵TRANSFORM Investigators, Basel, Switzerland
*Purpose: The development of pharmaceutical agents in transplantation is currently limited by long waits for hard endpoints. We sought to use a risk stratification system…
2020 American Transplant Congress
Noninvasive Detection of Subclinical Rejection in Urine RNA
K. S. Keslar¹, D. Margeta¹, J. J. Friedewald², M. Abecassis², R. B. Mannon³, P. S. Heeger⁴, R. L. Fairchild¹
¹Cleveland Clinic, Cleveland, OH, ²Northwestern University, Chicago, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Icahn School of Medicine, New York, NY
*Purpose: Subclinical rejection may lead to long-term graft injury and can currently only be detected by repeated biopsies. A noninvasive method is needed to monitor…
2020 American Transplant Congress
Three-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection – Early Impact of Interleukin-6 Blockade on Donor-Specific Antibody Levels, Rejection Morphology and Gene Expression
G. A. Böhmig¹, M. Dürr², B. Jilma³, F. Eskandary¹, E. Chong⁴, S. Schranz³, K. Doberer¹, M. Wahrmann¹, A. Borski¹, H. Regele⁵, J. Kläger⁵, R. Reindl-Schwaighofer¹, J. Reeve⁶, K. Budde², P. F. Halloran⁶
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Nephrology Department, Charité Berlin, Berlin, Germany, ³Dept. of Clin. Pharmacology, Medical University of Vienna, Vienna, Austria, ⁴Vitaeris Inc., Vancouver, BC, Canada, ⁵Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ⁶Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Targeting Interleukin-6 (IL-6) is a promising strategy to counteract antibody-mediated rejection (ABMR). This phase 2 trial (NCT03444103) was designed to evaluate the safety and…